This Week’s Biotech, Energy and Mining Stocks added to InvestorIdeas Directories

This Week’s Biotech, Energy and Mining Stocks added to InvestorIdeas Directories

Point Roberts, WA, Delta BC – March 3, 2017 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its investor membership, including global stock directories in biotech, energy and mining

Investorideas.com tracks companies in high profile trading sectors and makes ongoing additions to its stock directories for each sector.  Listing for the stock directories include companies on the TSX, OTC, NYSE, NASDAQ and global stock exchanges.

The latest biotech companies include Kalytera Therapeutics, Inc. (TSX: KALY.V) which is working with advancing CBD therapies and thus crosses into our cannabis stocks list.

The newest energy company is Molori Energy Inc. (TSX: MOL.V; OTCQB: MOLOF), an oil and gas production company with current operations in the Texas Panhandle.

Both new mining companies are Canadian listed and active in lithium as well as other metals and are also now listed on our renewable energy stock list in the lithium section. Power Americas Minerals Corp. (TSX:PAM.V) (formerly Victory Ventures) has operations in South America and is included in our North American stocks doing business in Latin America – Chile, Peru, Mexico and Colombia list.

Read this release in full at http://www.investorideas.com/news/2017/biotech/03031Stocks.asp

New Biotech Companies Added:

Kalytera Therapeutics, Inc. (TSX: KALY.V) is pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs. Kalytera is focused first on developing a new class of proprietary cannabidiol (“CBD”) therapeutics. CBD is a remarkable compound that has shown activity against a number of pharmacological targets. However, there are limitations associated with natural CBD, including its poor oral bioavailability and short half-life. Kalytera is developing innovative CBD formulations and prodrugs in an effort to overcome these limitations, and to target specific disease sites within the body. Kalytera intends to file composition of matter and method of use patents covering its novel inventions, with the goal of limiting future competition.

New Energy Companies Added:

Molori Energy Inc. (TSX: MOL.V; (OTCQB: MOLOF)  is an oil and gas production company with current operations in the Texas Panhandle. Founded in 2011, the experienced management team is aggressively acquiring select properties which provide immediate cash flow and development opportunities, now and in the years ahead. Molori is seizing the opportunity, in the current oil & gas environment, to assemble oil and gas production in nearby and politically safe jurisdictions. Molori is pursuing a business plan, whereby the Company either purchases producing oil and gas assets at highly attractive rates, or in some cases simply takes on existing assets by way of purchasing or assuming default notes from small regional lenders and institutions.

New Mining Companies Added:

One World Minerals Inc. (CSE:OWM) is a successful exploration and development Company with geologists having experience over the last 30 years in gold, silver, base metals and lithium.

Power Americas Minerals Corp. (TSX:PAM.V) (formerly Victory Ventures) acquisition strategy focuses on acquiring affordable, cost effective and highly regarded mineral properties in areas with proven geological potential. These areas include historical and currently producing mines with existing infrastructure. This strategy includes acquiring 100% interests in mineral properties, with no payment terms or work program commitments that would threaten a junior mining company's financial stability. The Company believes it can create maximum shareholder value efficiently and cost effectively implementing this acquisition strategy. The Company believes that the demand profile for Cobalt, Lithium, Copper, and other essential power related materials will be fundamentally led by the growing adaptation of electric vehicles, renewable energy and increased production of super alloys. With a focus on identifying and developing ethically sourced materials within the Americas, the Company intends to address the growing demand for energy metals that are being driven by innovation and the introduction of new technologies. Power Americas Minerals Corp. is a Canadian-based junior mining exploration company focused on the procurement, exploration and development of cobalt, lithium, copper and other energy metals in North and South America.

Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas

Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, company profiles, interviews and more in leading sectors.  

Sectors we cover include tech, bitcoin and blockchain, biotech, mining, energy, renewable energy, water stocks, marijuana and hemp stocks, food and beverage (including organic and LOHAS, wine), defense and security (including biometrics), Latin America, sports, entertainment, luxury brands and gaming.

The Investorideas.com content portfolio goes beyond the www.investorideas.com site to include 12 blogs on Blogger.com, 7 Artificial Intelligence (AI) websites on the Grid and the Waternewswire.com, all featuring Investorideas.com news and content.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:

From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

http://www.investorideas.com/membership/

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution,social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com

800-665-0411

Biodefense Stocks News: Aethlon Medical (NASDAQ: $AEMD) CEO Note: Bill Gates on the Threat of Bioterrorism

Biodefense Stocks News: Aethlon Medical (NASDAQ: $AEMD) CEO Note:  Bill Gates on the Threat of Bioterrorism

SAN DIEGO, CA (Investorideas Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), recently released the following note authored by its Chairman and CEO, Jim Joyce.

In a chilling address at the Munich Security Conference last Saturday, Bill Gates warned world leaders that a genetically engineered virus could kill more people than nuclear weapons. Mr. Gates expressed his concern, which is also supported by U.S. and U.K. intelligence agencies, that scientific terrorists have access to the necessary tools to design biological viruses to be weapons that could kill tens of millions of people. He also concluded that in the face of such knowledge, governments around the world remain complacent and are neither prepared nor equipped to respond to these threats.

If you are a shareholder of Aethlon Medical, you may recognize the concerns of Mr. Gates to be eerily similar to our own. As a recent example, I encourage you to review the bioterror related article that we published last year on the 21st of December.

http://aethlonmedical.investorroom.com/2016-12-21-Passage-of-the-21st-Century-Cures-Act-and-its-Potential-Implications-on-Biodefense

For those dedicated to the advancement of bioterror treatment solutions, Mr. Gates is a welcome and respected voice with the visibility, influence and knowledge to recognize that therapeutic innovation will be required to counter deadly viruses created by man.

If bioterrorists were to release such a virus, I am sincerely unaware of a clinical-stage candidate beyond our Hemopurifier® that could be deployed as a post-exposure treatment countermeasure.

The void in bioterrorism treatment countermeasures is driven by a historic emphasis to align a disease-specific drug or vaccine which only targets one specific pathogen threat. Such strategies have had limited success against the breadth of threats that are known to be infectious to man and cannot be considered as a strategy to treat unknown viruses created by man.

In reality, only a fraction of the 300+ viruses known to be infectious to man are addressed with an FDA-cleared drug or vaccine.  Since 2001, our government has spent an estimated $80 billion on biodefense initiatives, yet just one of 13 viruses classified as "Category A" are addressed with an approved therapy.  "Category A" pathogens are those biological threats that pose the highest risk to national security and public health.  In addition, these types of viral pathogens maintain the potential to be genetically engineered to be used as weapons that are even more deadly and resistant than those viruses that are naturally occurring.

Our Hemopurifier® is a first-in-class medical technology currently being advanced in FDA approved studies.  In previous studies, our technology has demonstrated the ability to capture a wide range of bioterror related, pandemic, chronic and latent infectious viral pathogens.

We believe the Hemopurifier® can fulfill the broad-spectrum medical countermeasure objective of the U.S. Department of Health and Human Services (HHS) Public Health Emergency Medical Countermeasure Enterprise (PHEMCE).  This initiative is directed toward bioterror, pandemic threats and other pathogens that are not well addressed with traditional drug or vaccine therapies.

A little more than a decade ago, we were invited to attend an international scientific symposium hosted by the National Center for Biodefense. At the time, our Hemopurifier® was still a development-stage vision. Regardless, the keynote speaker, who formerly led the Soviet Union's biological weapons program, emphasized our approach to be the only way to counter the breadth of viruses that could emerge naturally through mother nature or be created by man as agents of bioterror.

We never forgot that statement.

Read this release in full at http://www.investorideas.com/news/2017/biotech/03022AEMD.asp

About the Aethlon Hemopurifier®

The Aethlon Hemopurifier® is a first-in-class medical technology currently being advanced in FDA approved studies as a broad-spectrum treatment countermeasure against infectious viral pathogens.  Named a "Top 25 Invention" and one of the "Eleven Most Remarkable Advances in Healthcare," by TIME Magazine, the Hemopurifier® has previously been administered to individuals infected with Ebola virus, Hepatitis C virus and the Human Immunodeficiency virus, which leads to HIV AIDS.

Beyond human treatment experiences, pre-clinical Hemopurifier® studies have validated the capture of Chikungunya, Dengue, Middle East Respiratory Syndrome Coronavirus, West Nile and Zika virus, as well as Vaccinia and Monkey pox, which serve as models for human Smallpox infection.  Specific to pandemic influenza threats, Aethlon has validated the capture of H5N1 avian flu, H1N1 swine flu, and the reconstructed 1918 influenza virus, which represents a model for the strain of influenza that killed an estimated 50 million victims in 1918 and 1919.

The Hemopurifier has also been demonstrated to capture Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Herpes Simplex virus 1 (HSV1), which are latent viruses often associated with increased mortality in immune-suppressed sepsis patients.  These pathogens also contribute to organ rejection in transplant patients.  To validate treatment performance, the Hemopurifier is supported by the HP Virus Capture Assay, which quantifies the number of viruses captured within the Hemopurifier and no longer circulating in the patient.

About Aethlon Medical

Aethlon Medical (AEMD) is a leading developer of immunotherapeutic technologies to combat infectious disease and cancer.  To augment the body's natural immune defenses, the Aethlon Hemopurifier® eliminates life-threatening disease targets that are often shielded from the immune system and not well addressed by traditional drug therapies. The technology captures circulating viruses, bacterial toxins and cancer promoting exosomes through affinity attachment to a unique structure that cloaks these targets from immune detection. At present, the Hemopurifier® is being advanced under an FDA approved clinical study. Aethlon is also the majority owner of Exosome Sciences, Inc., a company focused on the discovery of exosomal biomarkers to diagnose and monitor life-threatening diseases.  Aethlon is part of the Russell Microcap® Index.  Additional information can be found online at www.AethlonMedical.com or you can connect with us on Twitter, LinkedIn, Facebook and Google+.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without limitation, the Company's ability to maintain its listing on the Nasdaq Capital Market, or any other national securities exchange, that the Company or its subsidiary will not be able to commercialize its products, that the FDA will not approve the initiation or continuation of the Company's clinical programs or provide market clearance of the Company's products, including any products relating to the Zika or MERS-CoV viruses or relating to sepsis, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies, the impact of government regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones contemplated in its contract with DARPA, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2016, and in the Company's other filings with the Securities and Exchange Commission. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Contacts:

Jim Frakes

Chief Financial Officer

Aethlon Medical, Inc.

858-489-7800 extension 3300

Jfrakes@aethlonmedical.com

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure: AEMD is a previous showcase company.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

BioDefenseStocks.com - investing ideas in biodefense stocks

Like Biodefense Stocks? View our Biodefense Stocks Directory

This Week’s Biotech, Nanotech and Mining Stocks also added to Investor Directories

This Week’s Biotech, Nanotech and Mining Stocks also added to Investor Directories

Point Roberts, WA, Delta BC – February 24, 2017 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its investor membership, including global stock directories in biotech, nanotech and mining

Investorideas.com tracks companies in high profile trading sectors and makes ongoing additions to its stock directories for each sector.  Listing for the stock directories include companies on the TSX, OTC, NYSE, NASDAQ and global stock exchanges.

The latest Biotech companies include those working with cannabinoids along with companies working in pain management, oncology, weight management, cystic fibrosis, OTC Medications, treatment for neurological diseases such as Alzheimer’s and ALS, kidney and vascular disease and new oral drug delivery systems.

Nanotech company additions coincide with a fully updated Nanotechnology stock list and include a cross-over company into the biotech sector, a company that provides nanotech tools and an investment company that has formed a joint partnership with Vietnam-based Nanotech firm.

See Nanotech stocks directory preview at http://www.investorideas.com/Nanotechnology/

New mining companies are both operating in Canada (Ontario and Quebec) and mining for copper and gold respectively.

Read this release in full at http://www.investorideas.com/news/2017/main/02241Stocks.asp

New Biotech Companies Added:

Arena Pharmaceuticals, Inc. (NasdaqGS:ARNA) a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight management in adults. One of the products under development is APD371, an agonist of the cannabinoid receptor 2 that is in Phase I single-ascending dose trial for the treatment of pain. The company also manufactures drug products under a manufacturing services agreement for Siegfried AG

Cara Therapeutics, Inc. (NasdaqGM:CARA) is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

Cerulean Pharma Inc. (NasdaqGM:CERU) The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting™ Platform to create a portfolio of nanoparticle-drug conjugates (NDCs) designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations. Our first platform-generated NDC clinical candidate, CRLX101, is in clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated NDC clinical candidate, CRLX301, is in a Phase 1/2a clinical trial.

Corbus Pharmaceuticals Holdings, Inc. (NasdaqGM:CRBP) is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, JBT- 101, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation, and fibrotic processes. In November 2016, Corbus reported positive topline data results from a Phase 2 study in diffuse cutaneous systemic sclerosis, showing clear signal of clinical benefit with JBT-101. The Company recently completed a Phase 2 study of JBT-101 for the treatment of cystic fibrosis with topline data expected to be announced before the end of the first quarter of 2017. Additionally, JBT-101 is being evaluated in a Phase 2, 12-month open label extension study in systemic sclerosis, a Phase 2 study in skin-predominant dermatomyositis, with a 12-month open label extension study in dermatomyositis and another Phase 2 study in systemic lupus erythematosus planned to commence in the first quarter of 2017.

CTT Pharmaceutical Holdings Inc. (OTCQB:CTTH) principal asset is a unique and novel patented drug delivery technology, an orally administered, fast dissolving thin film (the "Wafer"). This technology platform will target both the human and veterinarian (pet) markets for treatment of many diseases including pain management. The Oral Thin Film (Wafer) formulation is protected by several Canadian and US Patents. CTT's oral fast dissolving drug delivery systems will consist of edible thin films (wafers) that dissolve without water, within a few seconds after placement in the mouth. The majority of drugs administered using our drug delivery system mirror injections in that they have the ability to enter the bloodstream quickly, are convenient and discrete, and can be administered anywhere. A faster absorption rate is achieved because the mouth contains a very thin mucosa and is extremely vascular. There is no bitter taste, no smoke inhalation as is the case with cannabis, and less degradation of medication (by bypassing the stomach) and most importantly lower dosage units are required given the efficacy of absorption. Patient compliance is improved, especially with those who have a fear of choking and/or are pediatric, geriatric or incapacitated patients who have difficulty swallowing. Most fast dissolving systems on the market today deliver anti-inflammatories, antihistamines and cough and breathing related medications. CTT believes that its Wafer technology will be one of the first to gain use in major markets such as pain management.

Innovus Pharmaceuticals, Inc. (OTC: INNV) is an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which we market directly, (b) commercial partners to primary care physicians, urologists, gynecologists and therapists, and (c) directly to consumers through our on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.

Mateon Therapeutics, Inc. (NasdaqCM: MATN) is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in oncology. VTT includes vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA-approved and widely used in cancer treatment. These two approaches have distinct yet complementary mechanisms of action. At Mateon, we believe that we can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels. Mateon is committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide.

Mirna Therapeutics, Inc. (NasdaqGM: MIRN) is a clinical stage biopharmaceutical company developing a pipeline of microRNA-based oncology therapeutics and is the first to bring a synthetic microRNA mimic into clinical development for the treatment of cancer. Mirna's lead product candidate, MRX34, a mimic of naturally occurring microRNA-34 (miR-34), is being studied in a Phase 1 clinical trial which has included patients with primary liver cancer, advanced solid tumors and hematological malignancies. miR-34 is one of the most widely published microRNAs and is considered a key regulator of multiple oncogenes across key oncogenic pathways, with the capacity to regulate more than 30 different oncogenes and repress immune checkpoint signaling molecules, including PD-L1. The potential capacity to simultaneously affect multiple pathways and processes that are critical to cancer cell viability may make mimics of tumor suppressor microRNAs an important new class of anti-cancer agents. Mirna plans to develop MRX34 as a monotherapy and in combination with other therapies. The Company was founded in 2007 and is located in Austin, Texas.

Nivalis Therapeutics, Inc. (NasdaqGM: NVLS) is a pharmaceutical company that has historically been focused on the discovery and development of product candidates for patients with cystic fibrosis, or CF. Our GSNOR inhibitors selectively target an enzyme known as S-nitrosoglutathione reductase, which we refer to as GSNOR. GSNOR regulates levels of an endogenous protein known as S-nitrosoglutathione, or GSNO.  Depleted levels of GSNO have been associated with CF, asthma, inflammatory bowel diseases and certain cardiovascular diseases. However, in light of recent disappointing results of a Phase 2 clinical trial of our lead product candidate, cavosonstat, in CF, we determined to not pursue the development of this compound in CF and to wind down our research and development activities as we shift our strategic emphasis to investigating and evaluating strategic alternatives.

Oramed Pharmaceuticals Inc. (NasdaqCM: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (PODTM) technology is based on over 30 years of research by scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801).  The Company completed multiple Phase II clinical trials of ORMD-0801 under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).

ProMIS Neurosciences Inc. (TSX: PMN.TO) The mission of ProMIS Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and ALS. ProMIS Neurosciences' proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.

Proteon Therapeutics Inc. (NasdaqGM: PRTO) is committed to improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics. Proteon's lead product candidate, vonapanitase, is an investigational drug intended to improve hemodialysis vascular access outcomes. Proteon is currently enrolling patients in a Phase 3 clinical trial, PATENCY-2. Proteon is also evaluating vonapanitase in Phase 1 clinical trials in patients with peripheral artery disease (PAD).

New Nanotech Companies Added:

Cerulean Pharma Inc. (NasdaqGM:CERU) The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting™ Platform to create a portfolio of nanoparticle-drug conjugates (NDCs) designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations. Our first platform-generated NDC clinical candidate, CRLX101, is in clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Our second platform-generated NDC clinical candidate, CRLX301, is in a Phase 1/2a clinical trial.

Oxford Instruments PLC (LSE:OXIG.L) is a provider of technology tools and systems for industry and research. The Company operates through three segments: Nanotechnology Tools, Industrial Products and Service. The Nanotechnology Tools segment offers technology products serving research customers in both the public and private sectors. The Industrial Products segment contains a group of businesses supplying technology products and components manufactured in medium volume for industrial customers. The Service segment contains the Company's service, rental and refurbished asset sales business. Its NanoAnalysis business delivers solutions and services that enable materials characterization and sample manipulation at the nano scale. Its products are used on electron microscopes and ion-beam systems in academic institutions and industrial applications, including semi-conductors, renewable energy, mining, metallurgy and forensics. Its products include AZtecOne and X-Max Extreme detector, among others.

PHI Group Inc. (OTC:PHIL) primarily focuses on acquisitions as a principal and invests in energy, natural resources and special situations that may substantially enhance shareholder value.  In addition, the Company also provides merger and acquisition advisory services through its wholly owned subsidiary PHI Capital Holdings, Inc. and earns revenues in forms of cash and equity for services rendered. Nanotech – January 2017: signed an agreement with Nhat Hai New Technology JSC, a Vietnam-based company specializing in applied research and nanotechnologies (http://www.nanotechnology.com.vn), to form a joint venture company in the United States to apply the latter’s nanotechnologies for the production of various nano products.

New Mining Companies Added:

Hadley Mining Inc. (CSE:HM) is a Toronto based mineral company which owns 25% of the Pigeon River nickel-copper claim in Ontario.

Secova Metals Corp (TSX:SEK.V; OTC:SEKZF; Frankfurt: N4UN.F) is a Canadian gold exploration company focused on building a strong asset base through exploration of undervalued gold projects in Canada. Management has demonstrated expertise in advancing gold exploration projects into acquisition targets, most notably in the province of Quebec. Secova has the exclusive right and option to acquire from Tres-Or Resources Inc. ("Tres-Or"), an undivided 65% right, title and interest in the contiguous Duvay and Chenier Gold Projects. Secova can earn up to 90% of the property (an additional 25% ownership) by funding a pre-feasibility study after the initial exploration expenditures to bring the property towards production. The Company has a total contiguous land package of 174 claims covering over 7,766 hectares (17,458 acres) of land. Duvay/Chenier is located in the Abitibi gold belt, one of Quebec's premier mining jurisdictions. The Company has plans to advance the development of Duvay/Chenier as well as seek other avenues of growth through acquisition and mergers. The Company also has 100% ownership of the Eagle River project which is adjacent to and on-trend to several gold projects in the Windfall Lake district of Urban Barry in Quebec. The Company wholly owns the Cobalt Bay property which is 1,996 hectares and just 102kms north of its Eagle River project in Quebec.

Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas

Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, company profiles, interviews and more in leading sectors.  

Sectors we cover include tech, bitcoin and blockchain, biotech, mining, energy, renewable energy, water stocks, marijuana and hemp stocks, food and beverage (including organic and LOHAS, wine), defense and security (including biometrics), Latin America, sports, entertainment, luxury brands and gaming.

The Investorideas.com content portfolio goes beyond the www.investorideas.com site to include 12 blogs on Blogger.com, 7 Artificial Intelligence (AI) websites on the Grid and the Waternewswire.com, all featuring Investorideas.com news and content.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:

From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

http://www.investorideas.com/membership/

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution,social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com

800-665-0411

#InvestorIdeas Adds #Marijuana/ #Hemp, #Biotech, #Renewables, #Tech & #Defense #Stocks to Directories

This Week’s Marijuana/ Hemp Stocks Added; $ADVT, $CHIF, $ESSI

Also added in Marijuana/Cannabis/Hemp: $GLAG, $NEWC, $MYHI, $SIPC, $VAPE

Biotech, Renewables, Tech & Defense Stocks also added to Investor Directories

Point Roberts, WA, Delta BC – February 10, 2017 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its investor membership, including global stock directories in marijuana, biotech, renewables, tech and defense.

Investorideas.com tracks companies in high profile trading sectors and makes ongoing additions to its stock directories for each sector.  Listing for the stock directories include companies on the TSX, OTC, NYSE, NASDAQ and global stock exchanges.

Marijuana/Hemp companies added are involved in medical marijuana, a marijuana tech company, commercial hemp, CBD products, vaporization products and a company that provides a hemp infused beer called ‘Major Hemp Brown Ale’.

Biotech companies include Coherent, Inc. (NasdaqGS:COHR), one of the world’s leading providers of lasers, laser-based technologies and laser-based system solutions.  This company has also crossed over into our tech, defense and renewable (solar) stock lists. (see below).

Other biotech additions include companies involved in ophthalmology, including one that is helping people with visual prosthetics for the blind.  Also added are companies providing for patients suffering from PTSD, cancer and post surgical pain.

Our latest tech additions include the previously mentioned Coherent, Inc. (NasdaqGS:COHR), along with the Marijuana/Hemp listed stock Eco Science Solutions, Inc. (OTC:ESSI) which provide enterprise software to the alternative medicine and health and wellness sectors.  The company’s services also include localized communications between consumers and business operators, social networking with like-minded enthusiasts, rich educational content, e-commerce, and rapid delivery of products.

The newest defense companies include, along with Coherent, Inc. (NasdaqGS:COHR), Wesco Aircraft Holdings, Inc. (NYSE:WAIR), the world’s leading distributor and provider of comprehensive supply chain management services to the global aerospace industry.

Read this release in full at http://www.investorideas.com/news/2017/marijuana/02101Stocks.asp

New Marijuana Companies Added:

Advantis Corp (OTC:ADVT) develops products and works with developing companies to provide innovative healthcare products, holistic pain management solutions, and enhance the footprint in the evolving legal cannabis business. Advantis acquires ownership in developing companies that work within the nutraceutical and the alternative health care industries; consulting with these organizations to improve their product lines, expand their distribution channels through internal partnership agreements, and heighten brand value.

China Food & Beverage Company (OTC:CHIF) is a U.S. holding company whose strategy is the acquisition of companies in the medical cannabis industry, as well as the formation of joint venture partnerships and strategic alliances.

Eco Science Solutions, Inc. (OTC:ESSI) is a technology-focused Company based in Hawaii, targeting the multibillion-dollar health, wellness and alternative medicine industry. From enterprise software, to consumer applications for daily use, the Company develops technical solutions that empower enthusiasts in their pursuit and enjoyment of building eco-friendly businesses and living healthy lifestyles. Eco Science's core services span localized communications between consumers and business operators, social networking with like-minded enthusiasts, rich educational content, e-commerce, and rapid delivery of products, all catering to the health-and-wellness lifestyle.

Gala Global Inc (OTC:GLAG) is a publicly-traded company focused on the development and commercialization of cannabis derived products. The company is developing relationships with numerous groups within the cannabis and hemp industry as well as Indian Tribes looking to take advantage of the newly given opportunities by the federal government regarding cannabis on tribal lands. We are still in the process of developing a hemp fiber clothing line and a therapy line of nutraceutical CBD products. Gala Global, Inc., professional services group provides operational services and technologies that drive efficiencies in the medical and recreational cannabis market.

New Colombia Resources Inc (OTC:NEWC) is a two-pronged company with not only premium coking coal but medical marijuana operations, two of the hottest sectors in today's market. The Company has a joint venture in Colombia, Sannabis, producing medical marijuana products since 2014. New Colombia has hired a production company in Miami and teamed up with a retired World Series MVP to begin marketing some of these products in the U.S. where legal.

Mountain High Acquisitions Corp (OTC:MYHI) is a holding company focused on the commercial hemp and CBD products industries.  Our first acquisition in this sector is GreenLife BotaniX, Inc.

Sipp Industries Inc (OTC:SIPC) is a multifaceted corporation that specializes in technology, manufacturing and distribution of commercial and consumer products. Through its wholly owned subsidiary, Major Hemp, the Company provides high quality and competitively priced hemp based products, bulk hemp, CBD supply, co-packing and private labeling services, including “Major Hemp Brown Ale” brewed by Sleeping Giant Brewing of Colorado’

Vape Holdings Inc  (OTC:VAPE) focuses on designing, marketing, and distributing various vaporization products. The company offers medical and food grade ceramic products primarily under the HIVE Ceramics brand throughout North America, Europe and South America. HIVE offers a nonporous, non-corrosive, chemically inert ceramic vaporization element, which can be used for a range of applications, including stand-alone vaporization products and electronic cigarettes. The company is based in Agoura Hills, California.

New Biotech Companies Added:

Coherent, Inc. (NasdaqGS:COHR) is one of the world's leading providers of lasers, laser-based technologies and laser-based system solutions for scientific, commercial and industrial customers. Our common stock is listed on the Nasdaq Global Select Market and is part of the Russell 2000 and Standard & Poor's SmallCap 600 Index. Biotech

Presbia PLC (NasdaqGM: LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens™ has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens™ commenced in 2014.

Second Sight Medical Products, Inc. (NasdaqCM: EYES) mission is to develop, manufacture and market innovative implantable visual prosthetics to enable blind individuals to achieve greater independence. Second Sight has developed and manufactures the Argus II Retinal Prosthesis System. Second Sight is currently underway in a trial to test the safety and utility of the Argus II in individuals with Dry Age-Related Macular Degeneration. Second Sight is also developing the Orion™ | Visual Cortical Prosthesis to restore some vision to individuals who are blind due to causes other than preventable or treatable conditions. U.S. Headquarters are in Sylmar, California, and European Headquarters are in Lausanne, Switzerland.

Recro Pharma, Inc. (NasdaqCM: REPH) is a revenue-generating, specialty pharmaceutical company primarily focused on developing innovative products for hospitals and ambulatory care settings. The Company’s lead product candidate, injectable meloxicam, is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor that has successfully completed four Phase II clinical trials in the treatment of moderate to severe postoperative pain, and two pivotal Phase III clinical trials in patients following bunionectomy and abdominoplasty surgeries. As injectable meloxicam is not in the opioid class of drugs, the Company believes it will overcome many of the issues associated with commonly prescribed opioid therapeutics, including addiction, misuse\diversion, respiratory distress and constipation while maintaining analgesic, or pain relieving, effect.  In addition to developing proprietary drug candidates, Recro, through its subsidiary, Recro Gainesville LLC, leverages its formulation expertise to develop and manufacture pharmaceutical products using its proprietary delivery technologies for commercial partners who commercialize or plan to commercialize these products. These collaborations result in revenue streams including royalties, profit sharing, research and development and manufacturing, which support continued operations for Recro Gainesville as well as the Company’s research and development of proprietary product candidates.

Tonix Pharmaceuticals Holding Corp. (NasdaqGM: TNXP) is developing innovative pharmaceutical products to address current and emerging public health challenges, with two programs focusing on PTSD. TNX-102 SL is ready to start Phase 3 clinical trials and TNX-601 is in pre-IND stage of development. PTSD is a serious condition characterized by chronic disability, inadequate treatment options especially for military-related PTSD and overall high utilization of healthcare services creating significant economic burden. TNX-102 SL was recently granted Breakthrough Therapy designation by the FDA for the treatment of PTSD. Other development efforts include TNX-601, an IND drug candidate designed for daytime use for the treatment of PTSD, and TNX-801, a potential smallpox-preventing vaccine.

VBL Therapeutics (NasdaqGM: VBLT) Vascular Biogenics Ltd., operating as VBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The Company’s lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is positioned to treat a wide range of solid tumors. It is conveniently administered as an IV infusion once every two months. It has been observed to be well-tolerated in >200 cancer patients and we have observed its efficacy signals in an “all comers” Phase 1 trial as well as in three tumor-specific Phase 2 studies. Ofranergene obadenovec is currently being studied in a Phase 3 pivotal trial for recurrent Glioblastoma, conducted under an FDA Special Protocol Assessment (SPA).

New Renewable Companies Added:

Coherent, Inc. (NasdaqGS:COHR) is one of the world's leading providers of lasers, laser-based technologies and laser-based system solutions for scientific, commercial and industrial customers. Our common stock is listed on the Nasdaq Global Select Market and is part of the Russell 2000 and Standard & Poor's SmallCap 600 Index. Solar

New Tech Companies Added:

Coherent, Inc. (NasdaqGS:COHR) is one of the world's leading providers of lasers, laser-based technologies and laser-based system solutions for scientific, commercial and industrial customers. Our common stock is listed on the Nasdaq Global Select Market and is part of the Russell 2000 and Standard & Poor's SmallCap 600 Index. Solar

Eco Science Solutions, Inc. (OTC:ESSI) is a technology-focused Company based in Hawaii, targeting the multibillion-dollar health, wellness and alternative medicine industry. From enterprise software, to consumer applications for daily use, the Company develops technical solutions that empower enthusiasts in their pursuit and enjoyment of building eco-friendly businesses and living healthy lifestyles. Eco Science's core services span localized communications between consumers and business operators, social networking with like-minded enthusiasts, rich educational content, e-commerce, and rapid delivery of products, all catering to the health-and-wellness lifestyle.

New Defense Companies Added:

Coherent, Inc. (NasdaqGS:COHR) is one of the world's leading providers of lasers, laser-based technologies and laser-based system solutions for scientific, commercial and industrial customers. Our common stock is listed on the Nasdaq Global Select Market and is part of the Russell 2000 and Standard & Poor's SmallCap 600 Index. Defense

Wesco Aircraft Holdings, Inc. (NYSE:WAIR) is the world’s leading distributor and provider of comprehensive supply chain management services to the global aerospace industry, based on annual sales. The company’s services range from traditional distribution to the management of supplier relationships, quality assurance, kitting, just-in-time delivery and point-of-use inventory management. The company believes it offers one of the world’s broadest portfolios of aerospace products, including chemical, electrical and C-class hardware and comprised of more than 565,000 active SKUs.

Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas

Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, company profiles, interviews and more in leading sectors.  

Sectors we cover include tech, bitcoin and blockchain, biotech, mining, energy, renewable energy, water stocks, marijuana and hemp stocks, food and beverage (including organic and LOHAS, wine), defense and security (including biometrics), Latin America, sports, entertainment, luxury brands and gaming.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:

From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

http://www.investorideas.com/membership/

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution,social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com

800-665-0411